Gencure

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2013

Legal Domicile

Phone

2107579505

Tax Period

2024-01-01 to 2024-12-31

Gencure, founded in 2013, is a community nonprofit in the Health Care sector that reported $5.4M in total revenue in fiscal year 2024. Expenses of $16.0M exceeded revenue, resulting in a 196% operating deficit.

Mission

GENCURE IS ORGANIZED TO FOCUS ON REGENERATIVE MEDICINE AND THE UTILIZATION OF THE POWER OF HUMAN CELLS AND TISSUE TO ENHANCE LIVES AND ENABLE CLINICAL ADVANCEMENTS.

Program Service Accomplishments

Program 1

Expenses: $11,074,605 Revenue: $5,427,037

During the reporting year, the organization advanced its enterprise-wide quality and operational infrastructure through several key initiatives. The ISO 9001:2015 certification was successfully...

During the reporting year, the organization advanced its enterprise-wide quality and operational infrastructure through several key initiatives. The ISO 9001:2015 certification was successfully renewed and extended to the GenCure site, reinforcing alignment across the Quality Management System and ensuring consistent standards across manufacturing, testing, and clinical operations. A full GMP compliance audit was also completed, verifying adherence to FDA regulations and confirming cGMP readiness across bioproduction and testing facilities. The organization also advanced its quality assurance framework through successful execution of process validation and system qualification activities. These efforts ensured that critical production and testing systems operate consistently within defined parameters, supporting product integrity and regulatory compliance. By validating key processes and qualifying (Continued on Schedule O)

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $5,411,797

Investment Income $0

Other Revenue $15,240

TOTAL REVENUE $5,427,037

Expense Breakdown

Grants Paid $0

Salaries & Benefits $3,938,486

Fundraising Expenses $0

Program Expenses $11,074,605

Other Expenses $12,101,855

TOTAL EXPENSES $16,040,341

Year-over-Year Comparison

	2024	2023	Change
Revenue	$5,427,037	$5,040,198	+0.1%
Expenses	$16,040,341	$15,033,401	+0.1%
Net Income	$-10,613,304	$-9,993,203	+0.1%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

$374,356

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
BIOBRIDGE GLOBAL	SOLE MEMBER	1.0		$0	$0	$0
GEOFFREY KINDT	General Manager, Biomanufacturing (thru 11/02/2024)	50.0	Key Emp	$260,606	$84,913	$374,356
AMANDA WHITELONIS	Principal Global Market Development (effective 11/03/2024)	50.0	Highest	$20,119	$27,276	$219,270
MARI LANE SALMI	SR. DIRECTOR, PROCESS DEV & CELL THERAPIES	50.0	Highest	$203,361	$40,993	$244,354
Miguel Garza	Director, Operations Biomanufacturing	50.0	Highest	$156,301	$19,855	$176,156
MILTON MASAYUKI POLLARD	VP, GENCURE OPERATIONS (thru 07/09/2024)	50.0	Highest	$196,274	$23,473	$219,747
ROGELIO ZAMILPA	Executive Director, Biomanufacturing & Collab	50.0	Highest	$215,099	$27,522	$242,621

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$5,427,037	$16,040,341	$23,694,605	$-10,613,304
2023	$5,040,198	$15,033,401	$18,815,048	$-9,993,203
2022	$5,012,409	$13,721,023	$21,827,142	$-8,708,614
2021	$3,990,807	$10,638,729	$16,636,977	$-6,647,922
2020	$11,678,298	$21,889,542	$25,453,948	$-10,211,244
2019	$15,446,044	$21,802,879	$26,611,393	$-6,356,835
2018	$9,093,139	$22,588,583	$17,290,389	$-13,495,444